EPISODE · Feb 17, 2026 · 35 MIN
Overnight' Success's Cost? 25 Years – Propanc Biopharma CEO’s 25 Year Grind | Seth Farbman’s Podcast
from Seth Farbman on Podcast - From Startup to Stock Exchange · host Seth Farbman
What if cancer could be turned from a killer into a manageable chronic illness with no hair loss, no nausea, and no immunosuppression? In this gripping episode of Startup to Stock Exchange, host Seth Farbman goes deep with James Nathanielsz, CEO of NASDAQ-listed Propanc Biopharma (PPCB). From a 17-year grind raising over $30M, battling economic crashes, COVID, and regulatory wars, to compassionate-use stories where terminal patients defied odds and lived years longer, James reveals the science behind their novel proenzyme therapy PRP. Now NASDAQ-uplisted and gearing up for a landmark Phase 1b first-in-human trial in 2026 targeting advanced solid tumors like pancreatic and ovarian cancers, this could redefine treatment in massive markets. A raw, no-BS conversation on biotech perseverance, integrity in public markets, patient hope, and a potential game-changer that started with one doctor's desperate fight to save lives. Don't miss the underdog story that might just change everything. Seth’s Companies Vstock Transfer – https://www.vstocktransfer.com/ Share Media – https://www.sharemedia.co/ Listen to the Show Apple Podcasts – https://podcasts.apple.com/us/podcast/seth-farbman-on-podcast-from-startup-to-stock-exchange/id1356667808 Spotify – https://open.spotify.com/show/54i7xkWaAALAFrUvk4WZcN Connect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1 About the Show From Startup to Stock Exchange, hosted by entrepreneur and investor Seth Farbman, spotlights the journey of founders and CEOs as they scale their companies from early ideas to public markets. Each episode features candid conversations with leaders across industries, offering insights on growth, fundraising, branding, and the mindset it takes to build a company that lasts. 00:48 – Seth introduces James Nathanielsz & Propanc Biopharma (PPCB) 02:13 – Rambo scars analogy: 17+ years of entrepreneurial wars 03:08 – Propanc today: 17 years, $30M raised, NASDAQ uplist 2025 03:55 – Seth on the insane conviction needed for 17-year biotech grind 08:12 – Core motivation: helping families, belief the drug truly works 10:37 – Origin: 28-year-old mom gained 2 extra years via treatment 12:34 – 46 compassionate patients: 19 terminal cases beat huge odds, no side effects 15:26 – Vision: Turn metastatic cancer into a chronic illness game-changing 17:23 – “25 years of overnight success” 32:50 – Get treatment to patients fast, transformative potential Connect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1
Embed this episode
What this episode covers
What if cancer could be turned from a killer into a manageable chronic illness with no hair loss, no nausea, and no immunosuppression? In this gripping episode of Startup to Stock Exchange, host Seth Farbman goes deep with James Nathanielsz, CEO of NASDAQ-listed Propanc Biopharma (PPCB). From a 17-year grind raising over $30M, battling economic crashes, COVID, and regulatory wars, to compassionate-use stories where terminal patients defied odds and lived years longer, James reve...
Ready to play
Overnight' Success's Cost? 25 Years – Propanc Biopharma CEO’s 25 Year Grind | Seth Farbman’s Podcast
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.